Microvast (MVST) Is Up 14.9% After S&P Global BMI Addition and New Battery Launch

• In September 2025, Microvast Holdings was added to the S&P Global BMI Index and unveiled a suite of advanced battery products for high-demand industrial and vehicle uses at the Beijing International Construction Machinery, Building Material Machines, and Mining Machines Exhibition & Symposium (BICES 2025) in China.
• This dual development not only increases Microvast's visibility among institutional investors but also signals ongoing advances in high-performance, fast-charging battery solutions aimed at large-scale electrification sectors.
• We will now examine how Microvast’s expanded index inclusion and battery product showcase could influence its future business outlook and growth prospects.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Microvast Holdings Investment Narrative Recap

To be a shareholder in Microvast Holdings, you need conviction in global electrification and the company’s ability to translate high-performance battery innovations into commercial success. The recent S&P Global BMI Index inclusion and major product showcase should help improve institutional awareness and market recognition, yet the most important near-term catalyst, successful production ramp and commercialization of new batteries, faces ongoing execution risk, while exposure to China remains the central business risk not fundamentally altered by this news.

Among the recent announcements, the new suite of fast-charging batteries and next-generation MV-B and MV-C packs previewed at BICES 2025 stands out. These innovations, showing rapid charging and broad compatibility, directly address a key catalyst: Microvast’s effort to achieve higher-margin growth through advanced product adoption in industrial and vehicle fleets.

By contrast, investors should also keep in mind the continued concentration of manufacturing and operations in China, as...

Read the full narrative on Microvast Holdings (it's free!)

Microvast Holdings' narrative projects $726.7 million revenue and $78.9 million earnings by 2028. This requires 19.8% yearly revenue growth and a $192.2 million earnings increase from -$113.3 million today.

Uncover how Microvast Holdings' forecasts yield a $5.50 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Nine fair value estimates from the Simply Wall St Community range from US$2.50 to US$12.66 per share. While opinions vary, many see Microvast’s product pipeline as critical for future revenue streams; explore how others weigh the company’s innovation potential against regional and commercialization risks.

Explore 9 other fair value estimates on Microvast Holdings - why the stock might be worth over 2x more than the current price!

Build Your Own Microvast Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Microvast Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Microvast Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Microvast Holdings' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com